Non alcoholic fatty liver: Epidemiology and natural history

Reviews on Recent Clinical Trials

Volumn 9, Issue 3, 2014, Pages 126-133

  Masarone, Mario ^a   Federico, Alessandro ^b   Abenavoli, Ludovico ^c   Loguercio, Carmela ^b   Persico, Marcello ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

NAFLD Epidemiology; NAFLD Natural History; Non Alcoholic Fatty Liver Disease (NAFLD); Non Alcoholic Steato Hepatitis (NASH)

Indexed keywords

AGE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; ETHNICITY; GENDER; GENETICS; HISTORY; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; NON-ALCOHOLIC FATTY LIVER DISEASE;

HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84922321997     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666141216111143     Document Type: Article

References (114)

1. [1] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. [2] Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195-203.
3. [3] Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
4. [4] Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
5. [5] Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
6. [6] Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
7. [7] Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 13(37): 917-23.
8. [8] Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment PharmacolTher 2005; 22(S2): 64-70.
9. [9] Lonardo A, Loria P. NAFLD and cardiovascular risk: direct evidence for the tale of two ages. Am J Gastroenterol 2009; 104: 1851-2.
10. [10] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
11. [11] Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50: 1282-93.
12. [12] Nobili V, Reale A, Alisi A, et al. Elevated serum ALT in children presenting to the emergency unit: relationship with NAFLD. Dig Liver Dis 2009; 41: 749-52.
13. [13] Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002-9.
14. [14] Chan DF, Li AM, Chu WC, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004; 28: 1257-63.
15. [15] Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-93.
16. [16] Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect of weight changes on serum transaminase activities in obese children. ActaPaediatr Jpn 1997; 39: 210-214.
17. [17] Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
18. [18] Della CC, Ferrari F, Villani A, Nobili V. Epidemiology and Natural History of NAFLD. J Med Biochem 2014; 33: 1-5.
19. [19] Quinn SF, Gosnik BB. Characteristic sonographic signs of hepatic fatty infiltration. Am J Roentgenol 1985; 145: 753-5.
20. [20] Celle G, Savarino V, Picciotto A, Magnolia MR, Scalabrini P, Dodero M. Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studies with both techniques. Dig Dis Sci 1988; 33: 467-71.
21. [21] Siegelman S, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21: 71-80.
22. [22] Palmentieri B, De Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liv Dis 2006; 38: 485-9.
23. [23] Saadeh S, Younossi Z, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
24. [24] Halvorsen RA, Korobkin M, Ram PC, Thompson WM. CT appearance of focal fatty infiltration of the liver. Am J Roentgenol 1982; 139: 277-81.
25. [25] Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy and validation in vivo. Am J Physiol 1999; 276: E977-89.
26. [26] Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
27. [27] Gastaldelli A, Kozakova M, Højlund K, et al. RISC Investigators: Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-44.
28. [28] Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
29. [29] Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005; 41: 64-71.
30. [30] Whalley S, Puvanachandra P, Desai A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007; 7: 119-24.
31. [31] Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-91.
32. [32] Babusik P, Bilal M, Duris, I. Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors. Med Princ Pract 2012; 21: 56-62.
33. [33] Caballeria L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010; 22: 24-32.
34. [34] Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
35. [35] Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a ‘normal’ population: examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593-7.
36. [36] Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
37. [37] Dixon JB, Bhathal PS, O’Brien PE. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
38. [38] Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D. Liver damage in obese patients. Obes Surg 2002; 12: 802-4.
39. [39] Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349-55.
40. [40] Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
41. [41] Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16: 1087-93.
42. [42] Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 521-8.
43. [43] Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a ‘bright’ liver echopattern. Ital J Gastroenterol Hepatol 1997; 29: 351-6.
44. [44] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
45. [45] Patt CH, Yoo HY, Dibadj K, Flynn J, Thuluvath PJ. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci 2003; 48: 797-801.
46. [46] Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16.
47. [47] Mendez-Sanchez N. Non alcoholic fatty liver disease. Ann Hepatol 2009; 8(1): S3.
48. [48] Amarapurkar D, Kamani P, Patel N, et al. Prevalence of nonalcoholic fatty liver disease: population based study. Ann Hepatol 2007; 6: 161-3.
49. [49] Singh SP, Nayak S, Swain M, et al. Prevalenceofnon-alcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004; 25: 76-9.
50. [50] Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51(5): 1593-602.
51. [51] Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22, 788-93.
52. [52] Onyekwere CA, Ogbera AO, Balogun BO. Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. Ann Hepatol 2011; 10: 119-24.
53. [53] Caserta CA, Pendino GM, Amante A, et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intimamedia thickness in an adolescent population in southern Italy. Am J Epidemiol 2010; 171: 1195-202.
54. [54] Franzese A, Vajro P, Argenziano A, et al. Liver Involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-32.
55. [55] Sartorio A, Del Col A, Agosti F, et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007; 61: 877-83.
56. [56] Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-18.
57. [57] Radu C, Grigorescu M, Crisan D, et al. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis 2008; 17: 255-60.
58. [58] Berasain C, Betes M, Panizo A, et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000; 47: 429-35.
59. [59] Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2011; 34: 1139-44.
60. [60] Imhof A, Kratzer W, Boehm B, et al. Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007; 22: 889-97.
61. [61] Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gammaglutamyltranspeptidase levels. Hepatology 2009; 50: 1403-11.
62. [62] Zois CD, Baltayiannis GH, Bekiari A, et al. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol 2010; 16: 3944-9.
63. [63] Hwang S, Lee SG, Jang SJ, et al. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl 2004; 10: 721-5.
64. [64] Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.
65. [65] Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 650-6.
66. [66] Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on susected fatty liver in obese adolescents. Pediatrics 2005; 115: e561-5.
67. [67] Roesch-Dietlen F, Dorantes-Cuéllar A, Carrillo-Toledo MG, et al. Frequency of NAFLD in a group of patients with metabolic syndrome in Veracruz, Mexico. Rev Gastroenterol Mex 2006; 71: 446-52.
68. [68] Castro-Martínez MG, Banderas-Lares DZ, Ramírez-Martínez JC, Escobedo-de la Peña J. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir 2012; 80: 128-33.
69. [69] Araujo LM, De Oliveira DA, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab 1998; 24: 458-62.
70. [70] de Oliveira CP, de Mello ES, Alves V A, Saviero SM, Strauss E. Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. Ann Hepatol 2007; 6(4): 255-61.
71. [71] Boza C, Riquelme A, Ibañez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-53.
72. [72] El-Hassan AY, Ibrahim EM, al-Mulhim FA, Nabhan AA, Chammas MY. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992; 65: 774-8.
73. [73] Eshraghian A, Dabbaghmanesh MH, Eshraghian H, Fattahi MR, Omrani GR. Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors. Arch Iran Med 2013; 16(10): 584-9.
74. [74] Zelber-Sagi S, Lotan R, Shibolet O, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 2013; 33(9): 1406-12.
75. [75] El-Koofy N, El-Karaksy H, El-Akel W, et al. Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children. Eur J Radiol 2012; 81(11): 3120-3.
76. [76] Eguchi Y, Hyogo H, Ono M, et al; JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586-95.
77. [77] Park HS, Han JH, Choi KM, Kim SM. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005; 82: 1046-51.
78. [78] Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int 2007; 6: 572-8.
79. [79] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50(1): 204-10.
80. [80] Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009; 50(5): 1029-34.
81. [81] Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007; 22(9): 1482-9.
82. [82] Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. J Dig Dis 2007; 8(1): 58-64.
83. [83] Chow WC, Tai ES, Lian SC, Tan CK, Sng I, Ng HS. Significant non-alcoholic fatty liver disease is found in non-diabetic, pre-obese Chinese in Singapore. Singapore Med J 2007; 48(8): 752-7.
84. [84] Fan JG, Zhu J, Li XJ et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005; 20: 1825-32.
85. [85] Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
86. [86] Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
87. [87] Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian Indian men. Proc Natl Acad Sci USA 2006; 103: 18273-77.
88. [88] Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
89. [89] Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
90. [90] Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1567-76.
91. [91] Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: 1001324.
92. [92] Miele L, Beale G, Patman G, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008; 135: 282-91.
93. [93] Bechmann LP, Gastaldelli A, Vetter D, et al. Glucokinaselinks Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology 2012; 55: 1083-93.
94. [94] Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90.
95. [95] Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-9.
96. [96] Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
97. [97] Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
98. [98] Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology 2009; 55: 607-13.
99. [99] Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
100. [100] Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcoholinduced liver injury. Gastroenterology 1988; 95: 1056-62.
101. [101] Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-8.
102. [102] AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
103. [103] Loguercio C, De Simone T, D’Auria MV, et al, Italian AISF Clinical Group. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liv Dis 2004; 36: 398-405.
104. [104] Vanni E, Bugianesi E. Obesity and liver cancer. Clin Liver Dis 2014; 18: 191-203.
105. [105] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
106. [106] Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
107. [107] Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
108. [108] Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-44.
109. [109] Kohli R, Boyd T, Lake K, et al. Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr 2010; 50: 453-6.
110. [110] Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-9.
111. [111] Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
112. [112] Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
113. [113] White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-59.
114. [114] Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53(1): 325-35